Literature DB >> 16980200

Screening for primary aldosteronism.

Caroline Schirpenbach1, Martin Reincke.   

Abstract

Normokalaemic manifestation of primary aldosteronism is a frequent cause of secondary hypertension. It occurs in approximately 5-12% of all patients with hypertension, primarily patients with severe and uncontrolled blood pressure. Main causes are bilateral adrenal hyperplasia (2/3 of cases) and aldosterone-producing adenoma (1/3 of cases). Screening is performed by measurement of the aldosterone/renin ratio, which is raised in affected patients. Suspicion of primary aldosteronism due to a pathological ratio requires confirmatory testing e.g. by saline infusion test or fludrocortisone suppression test. If the diagnosis is confirmed, the underlying cause of aldosterone excess needs to be identified because therapy differs. First, adrenal imaging (CT/MRI) is performed, which is followed by postural testing in cases with a unilateral lesion. Concordant results confirm the diagnosis of an aldosterone-producing adenoma and allow treatment to proceed to adrenalectomy. In cases of equivocal results or normal/bilaterally enlarged adrenal glands on imaging, adrenal venous sampling must be performed for subtype differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980200     DOI: 10.1016/j.beem.2006.07.007

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  2 in total

1.  [Other specific types of diabetes].

Authors:  Greisa Vila; Alois W Gessl; Michaela Riedl; Anton Luger
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

2.  Renin angiotensin aldosterone system altered in resistant hypertension in Sub-Saharan African diabetes patients without evidence of primary hyperaldosteronism.

Authors:  Bertille Elodie Edinga-Melenge; Vicky J Ama Moor; Jobert Richie N Nansseu; Romance Nguetse Djoumessi; Michel K Mengnjo; Jean-Claude Katte; Jean Jacques N Noubiap; Eugene Sobngwi
Journal:  JRSM Cardiovasc Dis       Date:  2017-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.